Literature DB >> 7927837

Prevalence of ciprofloxacin resistance in multiresistant gram-negative intensive care unit isolates.

C M Khurana1, B R Wojack.   

Abstract

Of 107 gram-negative isolates obtained from intensive care units examined for patterns of multiresistance to 16 antimicrobial agents, 54.2% were multiresistant, defined as resistant to three or more test antimicrobials. Ciprofloxacin had excellent activity against all isolates with 93.4% susceptibility. Ciprofloxacin also performed well on multiresistant isolates with 89.7% susceptibility, which included 42.2% inducible Enterobacteriaceae. All six multiresistant ciprofloxacin-resistant isolates were resistant to five or more of the tested antimicrobials (mean 9.0), including a highly resistant Proteus mirabilis urine isolate resistant to 14 of 16 agents. The only antimicrobial to which all of the ciprofloxacin-multi-resistant isolates were resistant, was ampicillin, indicating an absence of cross resistance. In addition, ciprofloxacin had excellent activity (100% susceptibility) against Enterobacter spp. and Klebsiella pneumoniae, two organisms frequently associated with nosocomial infections.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927837     DOI: 10.1007/bf01793573

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  New beta-lactams: new problems for the internist.

Authors:  C C Sanders
Journal:  Ann Intern Med       Date:  1991-10-15       Impact factor: 25.391

2.  Resistance development to fluoroquinolones in Europe.

Authors:  B Wiedemann; M T Zühlsdorf
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

Review 3.  Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins.

Authors:  W E Sanders; C C Sanders
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

Review 4.  Chromosomal cephalosporinases responsible for multiple resistance to newer beta-lactam antibiotics.

Authors:  C C Sanders
Journal:  Annu Rev Microbiol       Date:  1987       Impact factor: 15.500

Review 5.  Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches.

Authors:  P Ball
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

Review 6.  A review of the antimicrobial activity of the fluoroquinolones.

Authors:  P Maple; W Brumfitt; J M Hamilton-Miller
Journal:  J Chemother       Date:  1990-10       Impact factor: 1.714

7.  Quinolone resistance. Susceptibility data from a 300-bed community hospital.

Authors:  M F Parry; K B Panzer; M E Yukna
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

Review 8.  In vitro activity of ciprofloxacin against gram-positive bacteria. An overview.

Authors:  F H Kayser; J Novak
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

9.  Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

10.  Clinical implications of multi-drug resistance in the intensive care unit.

Authors:  D R Snydman
Journal:  Scand J Infect Dis Suppl       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.